This document contains financial and operational metrics for a district covering the months of November and projections for Q3. Key highlights include 102% attainment of annual operating plan for the first half, 10% implant growth, and ranking 2nd nationally in test stacking. Game changing opportunities noted are increasing the test pipeline, new implant growth, and new account development.

1. Kansas City, MO
November 3rd & 4th

2. Mark Hardesty
Charlie Cobbs
Chris Schulteis
Chris Qamoos
Jason Williams
Bill Konen
Jackie HaydockKnick Davis
Pat Giller

3. ◦ 102% of AOP
◦ Flat Implant Growth
◦ -3% New Implant Growth
◦ 4% Revenue Growth
◦ 6% Load (36 units)
◦ 82% Conversion Rate
◦ 284 ACT vs 304 REQ Tests (-20)
◦ 285 ACT vs 272 REQ Implants (+13)
◦ Sequential Quarterly Implant
Growth

4. PRP
Activity
PRP
Rank
Stack
BEs per
HC
Stack
Rank
New
Docs
per HC
New
Doc
Rank
Qrtle
Maint
Qrtle
Maint
Rank
Nat’l
Rank
% to
Plan
New
Implant
Growth
Qamoos/
Cobb
45% 3rd 5 18th 0 55th -2% 90th 29th 121% -20%
Schulteis
/Davis
19% 86th 3 48th 1 11th -21% 128th 70th 105% 33%
Konen/W
illiams
4% 178th 5 18th 0 55th 10% 59th 89th 83% -23%
Haydock 62% 19th 1 96th 0 55th -4% 99th 68th 78% -22%
Giller 5% 175th 3 48th 0 55th -39% 154th 161st 72% -34%
DISTRICT 24% 13th 4 2nd .3 12th -3% 12th 10th 102% -3%

5. On Deck New Accounts Implants
Qamoos/Cobbs 3* 0 0
Schulteis/Davis 1 2* 18
Konen/Williams 0 0 0
Giller 1 0 0
Haydock 1 0 0
DISTRICT 6 2 18
Note: Reflects Regis as of 1/30
* Reflects CR

6.  MTD November
◦ 88 Tests PROJ vs. 95
REQ (-7)
◦ 88 Implants PROJ vs. 66
REQ (+22)
◦ 100% of AOP
◦ 11% Implant Growth
◦ UNLOAD 22 Units(-33%)
*Note: Q3 Run Rt. for Tests & Implants (13 wks.)
Tests-22/Wk. & Implants-22/Wk. x 4 Wks

7. • Tests: 286 Projected vs. 417
REQ (-131)
• Implants: 286 Projected vs.
288 REQ (-2)
• 100% of AOP
• 18% Implant Growth
• 1% Load (2 Units)
*Note Q3 Run Rt. For Tests & Implants (13 Wks.)
Tests: 22/Wk. & Implants: 22/Wk. x 13 Wks.

8.  “Key Highlights”
• 102% of AOP for 1st Half
• District ranked 10th in Core 4
Ranking
• Sequential Quarterly Implant
Growth
• Ranked 2nd Nationally in
Stacking
• Good Momentum into 2nd Half
• Strong CAGR Growth Rates
• Implants (8% & 14%)
• Revenue (9% & 18%)
 “Game Changing Opportunities”
• Driving Test Pipeline
• New Implant Growth
• Quartile Maintenance
• New Account Development
• Watch Test Trends

9. 0 500 1000 1500
FY09
FY10
FY11
FY12
FY13
FY14
Implant CAGR
$0 $5,000 $10,000 $15,000 $20,000
FY09
FY10
FY11
FY12
FY13
FY14
Revenue CAGR
0 100 200 300 400
Q1FY14
Q2FY14
Q3FY14
Q4FY14
Q1FY15
Q2FY15
Sequential Test Trend Growth
250 260 270 280 290 300 310
Q1FY14
Q2FY14
Q3FY14
Q4FY14
Q1FY15
Q2FY15
Sequential Implant Trend Growth

10.  1st Half Results
◦ 83% of AOP
◦ -13% Implant Growth
◦ -23% New Implant
Growth
◦ 32 ACT vs. 30 REQ Tests
(+2)
◦ 32 ACT vs. 26 REQ
Implants (+6)
◦ -20% Revenue Growth
◦ 82% Conv. Rate YTD
◦ -2% LOAD (2 Units)

11.  November
Projections
◦ 10 Tests PROJ vs. 10
REQ
◦ 10 Implants PROJ vs.
7 REQ (+3)
◦ 25% Implant Growth
◦ 100% of AOP
◦ UNLOAD (-3 Units)
 Q3 Trends Outlook
◦ 32 PROJ Tests vs. 42
REQ (-10)
◦ 32 PROJ Implants vs.
31 REQ (+1)
◦ 100% of AOP w
Upside
◦ 28% Implant Growth
◦ NO LOAD
*Note: February Tests & Implants based on Q3 Run Rt. (13 Wks)
Tests: 2/Wk. and Implants: 2/Wk.
*Note: Q4 Tests & Implants based on Q3 Run Rate (13 Wks)
Tests: 2/Wk and Implants: 2/Wk

12.  “Key Highlights”
• Momentum building from Q1 to Q2
• Phoenix Urology is up 20% due to Bladder
Mailer
• KC Urology Care & Phoenix Urology are
receptive to implementing CPO Process
• Burk, New GYN is completing elearning w/
patients identified for stacked day
• Sustain and accelerate Q2 Trends
 “Comeback Opportunities”
• -23% New Implant Growth
• KC Urology is down 17%
• Driving Test Pipeline
• PRP & LTPS Activity
• New Account Development
• Engagement of KC and Phoenix Urology
Partners w/ CPO Process
• Focus on CRS and GI opportunity

13.  1st Half Results
◦ 72% of AOP
◦ -32% Total Implant
Growth
◦ -9% Revenue Growth
◦ -30% New Implant
Growth
◦ 54 ACT vs. 74 REQ Tests
(-20)
◦ 39 ACT vs. 50 REQ
Implants (-11)
◦ 63% Conv. Rate YTD
◦ NO LOAD YTD
Pat Giller and Bret Saberhagen

14.  November
Projections
◦ 10 Tests PROJ vs. 9
REQ (+3)
◦ 13 Implants PROJ vs.
7 REQ (+6)
◦ 100% of AOP
◦ 160% Implant Growth
◦ UNLOAD (6 Units)
 Q3 Trends Outlook
◦ 32 PROJ Tests vs. 39
REQ (-7)
◦ 45 PROJ Implants vs.
32 REQ (+13)
◦ 100% of AOP w/
Upside
◦ 105% Implant Growth
◦ NO LOAD
*Note: February Tests & Implants based on Dec & Jan Run Rt. (9 Wks)
Tests: 2.4/Wk. and Implants: 3.4/Wk.
*Note: Q4 Tests & Implants based on Dec & Jan Run Rate (9 Wks)
Tests: 2.44/Wk and Implants: 3.44/Wk w/ 80% Conv. Rate

15.  “Key Highlights”
◦ 2 New Docs in
Development (Zoorob &
Carey)
◦ Dahl will attend PFF, has 9
tests scheduled Nov & Dec
 “Momentum Builders”
◦ Quartile 1&2 Docs Decline
◦ Integrating CPO & LTPS
◦ New Account Development
◦ No CR Activity

16.  “A simple, repeatable and proven formula for
executing on your most important strategic
priorities in the midst of the whirlwind.”
1. Focusing on the Wildly Important
2. Acting on lead measures
3. Keeping a Compelling Scoreboard
4. Creating a cadence of accountability
Leaders can produce breakthrough results!

17. WIG
nLink Reports
Expense Reports
Weekly Conference Calls
Patient Calls
Online Credentialing Courses
Updating Unscheduled Tests
Reports

18. Hits Runs OBP BA Record
2014 1456 651 .314 .263 89-73
2013 1443 648 .315 .260 86-76
Hits Runs OBP BA Record
Royals 130 69 .314 254
Giants 154 71 .324 257
KC Royals 2014 vs. 2013 Stats
Post Season Stats

19.  Building a “True Pelvic Floor” Center of
Excellence
 Executing an “ASC Strategy Framework”
 Perception vs. Reality